COMMITMENT TO LATIN AMERICA & AFRICA
IN-DEPTH TECHNICAL & INVESTMENT KNOWLEDGE
TRACK RECORD IN HEALTHcARE TRANSACTIONS
CEO & PRINCIPAL PARTNER
Gabby Cezar founded Panarea Partners in October 2015 with leading US investors to deliver business growth & investments to healthcare and life sciences in Latin America & Africa. She has 10+ years of exclusive focus in growth markets and a remarkable track record in R&D and commercial transactions in countries like Brazil, Argentina, Chile and South Africa, with US$500MM in investments across multiple projects and programs she created and delivered to Latin America between 2009 and 20015. From 2012 until October 2015, Dr. Cezar served as Senior Director and Head of Pfizer ERDI (External Research & Development Innovation) in Latin America and South Africa. She is also the co-founder and former Chief Scientific Officer of Stemina Biomarker Discovery, in Madison, WI, which commercializes stem cell metabolomics and biomarkers based on her intellectual property at University of Wisconsin-Madison. Stemina is currently advancing the largest US-based clinical trial for a candidate metabolomics-based autism diagnostic.
She was a former senior scientist in Pfizer´s Global Research and Development in Groton, CT, USA, and an Assistant Professor at the University of Wisconsin-Madison (USA), where she was awarded NIH (National Institutes of Health) investments for her research programs in stem cell biology and neurodevelopmental disorders. From 2008-March 2012, as Managing Director Latin America of Burrill & Company, a US-based venture capital firm, Gabby led the fund raising and development of a US$120MM life sciences-focused venture capital fund in Brazil, where Pfizer Ventures is one of the investors, along with leading regional institutional (BNDES, FINEP, FUNCEF, Investe Rio, Desenvolve SP, CAF, IADB-Fumin) and strategic private investors (Thermo Fisher Scientific, former Life Technologies).
Dr. Cezar has been recognized with important global life sciences industry awards, namely a W.E. Upjohn Award and Pfizer Worldwide Innovation Award in 2013, "Top 40 Under 40" from InBusiness magazine, and was named by Forbes Magazine as “one of twelve stem cell revolutionaries” in 2008. She received a Veterinary Medicine degree from UFMS (Brazil), MS from Universidade de Brasilia (Brazil), MS from The University of Edinburgh (Scotland) and a PhD from the University of Wisconsin-Madison (USA).
Fred Craves, PhD, is the Founder of Bay City Capital. Since launching the firm in 1997, Fred has built Bay City Capital to become one of the world’s premier life science investment firms investing in nearly 100 companies and raising more than $1.6 billion.
As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture backed biotech company at that time.
He has served as Executive Vice President of Schering Berlin, Chief Executive Officer and President of Berlex Biosciences, Founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules.
Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of Madrigal Pharmaceuticals, Reset Therapeutics and Dermira. Previous investments and board participation, in addition to Reliant, include Medarex, Incyte Pharmaceuticals, and Ion Torrent. Dr. Craves serves as a member of The J. David Gladstone Institutes’ Advisory Council and as a member of the Board of Trustees of Loyola Marymount University in Los Angeles. He earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.
Dr. Shelley Ann des Etages-Wong has over ten years of experience in the pharmaceutical sector where she specialized in using genomic approaches in the identification and validation of drug targets and biomarkers across multiple therapeutic areas. Dr. des Etages-Wong also engaged in due diligence evaluation of technologies and played a key role in Pfizer collaborations and transactions with academic and industry partners. Her efforts included associations with Affymetrix Inc., Gene Logic, Ingenuity, Gene News and Gene Expression Inc. among others. She is a recipient of both the Pfizer Achievement and People Leader Awards. Dr. des Etages-Wong holds a certificate in Drug Development from Temple University School of Pharmacy and a doctorate in Microbiology and Molecular Genetics from Rutgers University.
SHELLEY DES ETAGES-WONG
BRUNO BONI DE OLIVEIRA
Mr. Oliveira holds an MS from Columbia University in Sustainability Management and a BS in Economics from PUC-Rio, Brazil. He is an Associate at Panarea Partners, and a Partner and lead Environmental and Financial Strategist of Rede Vanguarda TV, São José dos Campos, SP. He is the President of the Deliberative Council of Instituto Eco Amazônia (NGO), Manaus, Amazonas. Previously, Mr. Oliveira was a Sustainable Forestry Project Manager and Intern at FIDES Asset Management, Rio de Janeiro, RJ, Brazil.
Tim is a Partner and Co-Founder of Torreya Partners, a premier US boutique healthcare investment banking firm launched in 2007, after a career working in large investments banks and being an academic researcher in finance. Tim takes pride in providing rigorous long-term advice to companies. He has completed more than 150 life sciences financing, licensing and M&A transactions with a value in excess of $100 billion. Tim was previously VP of Strategy at FibroGen; a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and a finance professor at the Ohio State University. He received a Ph.D. in Economics from UCLA and a B.A. from Florida State University.
Director, Real Estate Development,
Latin America Diagnostics Hub
Ms Gebrin holds a Postgraduate degree in "Cities, Environment and Public Policies" from UFPR, Curitiba - Brazil, a degree in Architecture and Urbanism from UNIDERP - Brazil and a Diploma in Architectural Technology from Napier University, Edinburgh, Scotland. She is an advisor at Panarea Partners. She has professional experience in Edinburgh and in New York. Previously, Ms Gebrin was a partner of De Fournier & Associates
(from 2010 to 2017), now under a new company name DEF Projetos, with more than 190 million square meters urbanized areas in its portfolio.
Ms. Almeida has provided investment banking and financial advisory services to companies in Latin America for over 20 years. Ms. Almeida is currently an advisor at a Fund management company dedicated to investments in real assets in Brazil. Ms. Almeida was a Director of Violy&Co., an M&A advisory company focused on family-owned businesses and family offices in Latin America. Before joining Violy&Co., Ms. Almeida was a managing director of Trust Company of the Atlantic (“TCA”), a management buyout of the emerging markets division of Wasserstein Perella & Co. (“WP&Co.”). At WP&Co. and then at TCA, Ms. Almeida managed much of Latin American capital markets product development, including new issues, structured finance and restructurings. She was responsible for creating the first securitizations of tax receivables in Argentina, the first car loans securitizations in Brazil and many other asset-backed transactions throughout Latin America. At WP&Co., she marketed and executed principal investments and M&A transactions in Latin America. During her time at WP&Co., Ms. Almeida worked on deals totaling US$2B, including the privatization of Embraer. Prior to joining WP&Co., Ms. Almeida was vice president for M&A and international project finance for CR Almeida Group, one of Brazil’s largest engineering and logistics companies. Ms. Almeida started her career as a University Professor of Engineering and Computational Mechanics at Universidade Federal do Paraná, Brazil. Ms. Almeida holds a B.S. in civil engineering from Universidade Federal do Paraná, and an MSc and an Engineer’s Degree from Stanford University.
Jay D Kranzler, MD, PhD has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Chief Executive Officer of Perception Neurosciences, a company developing drugs targeting the Central Nervous System (CNS), co-founded by Dr. Kranzler. He is a Board Member of several biotechnology companies including Pastorus, Avenue Pharmaceuticals, and ImmunoBrain Checkpoint, and provides consulting services to multiple large pharmaceutical companies, small biotechnology companies, investment banks, and investors.
After graduating from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology, Dr. Kranzler joined McKinsey & Company where he was instrumental in establishing the Firm’s pharmaceutical practice. In 1989 he became the Chief Executive Officer of Cytel Corporation, a company focused on the development of immunomodulatory drugs. He took Cytel public, and negotiated partnerships with both global and Japanese pharmaceutical companies that set new standards for deal size and structure. After Cytel, Dr. Kranzler became Chief Executive Officer of Cypress Bioscience (formerly IMRE Corporation) where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia, and Karuna Pharmaceuticals, focusing on the treatment of Schizophrenia.
Dr. Kranzler joined the Pfizer in April 2013, becoming Vice President, Head of External R&D Innovation Pharmatherapeutics and Strategic Investments, with responsibility for multiple therapeutic areas and technologies including Neuroscience, Pain, Rare Diseases, and Gene Therapy, as well as with developing and leading Pfizer’s R&Dnnovate Venture Fund.
During his career, Dr. Kranzler has developed drugs, medical devices, as well as diagnostics, and is the inventor on over 30 patents. Dr. Kranzler received the Innovator award from the International Society of CNS Clinical Development, has been nominated twice as the “Entrepreneur of the Year” and is an Adjunct Professor, New York University Stern School of Business and School of Medicine, serves on The NYU Entrepreneurial Institute’s Advisory Board, and was an Executive in Residence at UCSD’s Rady School of Management.
PARTNER AT MINTZ LEVIN
Daniel is Co-chair of the firm's Venture Capital & Emerging Companies Practice. In addition to his active legal practice, he is an adjunct professor of law at the NYU Law School and he has a wealth of experience in private equity and venture capital, having co-founded Dawntreader Ventures, an early stage venture capital firm based in New York.
Daniel's practice focuses on representing emerging technology companies, venture capital, private equity, sports and entertainment, corporate governance, and general corporate law. Before joining Mintz Levin, Daniel was head of venture capital funds and a managing director of SoundView Technology Group, Inc. (formerly Wit Capital), a technology-focused investment bank. Prior to joining SoundView, he was head of the corporate and new media and e-law practice groups at one of the leading New York firms representing early stage and technology companies.
Daniel has more than 30 years of corporate transactional experience, both as a lawyer and as a businessman, and has been an advisor to many emerging and developmental stage companies. He is a board member of several technology companies and a managing director of Dawntreader Ventures.
Additionally, Daniel is an author of a leading treatise on venture capital called Venture Capital: Forms and Analysis (Law Journal Press, 2007).